St. John's Wort: Evidence-Based Guide to Benefits, Dosing, and Safety

St. John's Wort: Evidence-Based Guide to Benefits, Dosing, and Safety

Last Updated:

St. John's wort (Hypericum perforatum) is a flowering plant used medicinally for centuries across Greek, Islamic, and Chinese traditional medicine systems [1][2]. The aerial parts contain at least seven groups of bioactive compounds, including naphthodianthrons (hypericin), flavonoids (quercetin), and phloroglucinol derivatives (hyperforin) [1][4]. Multiple meta-analyses confirm it is as effective as standard antidepressant medications for mild to moderate depression, with significantly fewer side effects [8][9].

The most significant concern is its extensive drug interaction profile — it can reduce the effectiveness of approximately half of all medications in use today [1].

Table of Contents

Overview

St. John's wort (Hypericum perforatum) is a perennial plant native to Europe, North Africa, and western Asia, now naturalized across much of North America, Australia, and other temperate regions [2]. The plant's name refers to John the Baptist, as it blooms around his feast day in late June. It is also known as hypericum, Klamath weed, and goatweed [2].

The medicinal parts are the aerial portions — the flowers, leaves, and stems (not the roots) [1]. St. John's wort contains at least seven groups of biologically active constituents, including naphthodianthrons (e.g., hypericin), flavonoids (e.g., quercetin), bioflavonoids (e.g., biapigenin), xanthones, and phloroglucinol derivatives (e.g., hyperforin) [1][4]. Of these, hypericin and hyperforin have received the most research attention, though current evidence suggests the therapeutic effect arises from synergistic interactions among multiple compounds rather than any single constituent [5][6][7].

The NIH National Center for Complementary and Integrative Health (NCCIH) confirms that St. John's wort appears more effective than placebo and as effective as standard antidepressants for mild to moderate depression [2]. For severe major depression (often requiring hospitalization), standard antidepressants are considered more effective [1][2][3].

St. John's wort does not cause euphoria and, like conventional antidepressants, is unlikely to elevate mood in people who are not truly depressed [1]. As with standard antidepressants, it takes several weeks to achieve full therapeutic effects [1].

Despite its efficacy for mild-to-moderate depression, St. John's wort carries significant safety risks, particularly extensive drug interactions. It can reduce the blood levels and effectiveness of oral contraceptives, HIV antiretrovirals, immunosuppressants, chemotherapy agents, blood thinners, and statins, among many others [1][2][10][11]. Always consult a healthcare provider before using St. John's wort if taking any medication.

Forms and Bioavailability

Extract vs. Whole Herb

St. John's wort products come in two primary forms: standardized extracts and whole herb preparations. Virtually all clinical trials demonstrating efficacy have used standardized extracts rather than whole herb preparations [1][12].

Form Standardization Typical Dose Notes
Standardized Extract (0.3% hypericin) ~0.3% hypericin 300 mg three times daily (900 mg/day) Most studied form; the majority of positive clinical trials used this preparation [1][12].
Standardized Extract (0.3% hypericin + 1–3% hyperforin) Both hypericin and hyperforin standardized 300 mg three times daily (900 mg/day) Dual-standardized preparations used in several positive trials, including the landmark Szegedi (2005) BMJ trial [1][9].
Whole Herb (dried, powdered) 0.1–0.15% hypericin 2–4 g/day in divided doses Less studied. May contain higher heavy metal concentrations than extracts, as some contaminants are removed during extraction [1].
Liquid Extract / Tincture Variable Per manufacturer directions Less clinical data than solid extracts; standardization varies widely between products [1].
Topical Preparations (Oil/Cream) Variable Applied to skin Promoted for wound healing and skin conditions; limited human clinical evidence [2][14].

Active Constituents

Hypericin is the primary marker compound used for standardization in most commercial products and clinical trials. Products standardized to 0.3% hypericin have consistently proven effective in human studies [1][12]. However, hypericin may not be the most pharmacologically important constituent [1][13].

Hyperforin has been identified as a major antidepressant component of St. John's wort [13]. It inhibits the reuptake of serotonin, norepinephrine, dopamine, GABA, and L-glutamate — a broader mechanism than SSRIs, which primarily affect serotonin alone [5][13]. Some products are additionally standardized to 1–3% hyperforin content [1].

Synergistic mechanism: Newer research suggests that the benefit of St. John's wort arises from synergistic interactions among multiple compounds rather than the pharmacological activity of any single constituent [5][6][7]. Butterweck (2007) demonstrated that the extract's antidepressant properties emerge from the combined action of hypericin, hyperforin, flavonoids, and other constituents [5]. Reichling (2003) reached similar conclusions regarding the importance of the whole phytochemical profile [7].

Bioavailability Considerations

Key factors when selecting a St. John's wort supplement:

  • Standardization: Look for products standardized to at least 0.3% hypericin. Dual standardization to hyperforin (1–3%) provides additional assurance of active ingredient content [1].
  • Plant parts used: Labels should indicate flowers and leaves (or "aerial portions"), not roots [1].
  • Extract vs. whole herb: Standardized extracts are preferred over whole herb preparations based on the clinical trial evidence base and lower heavy metal risk [1].
  • Onset of action: Like conventional antidepressants, St. John's wort takes several weeks of consistent use to achieve full therapeutic effects [1][2].

Evidence for Benefits

Depression (Mild to Moderate)

This is the most robustly studied indication. Major depression of mild to moderate severity is a clinical diagnosis — it refers to a more serious level of depression than mere "blues" or transient low mood [1].

Cochrane systematic review (2008): Linde and colleagues conducted a comprehensive review of the totality of evidence for St. John's wort in major depression. The review concluded that St. John's wort extracts are superior to placebo in patients with major depression, similarly effective to standard antidepressants, and associated with fewer side effects [8].

Meta-analysis vs. SSRIs (2023): Zhao et al. analyzed randomized clinical trials directly comparing St. John's wort extract with SSRIs in adults with depression. The analysis found comparable efficacy to SSRIs and a significantly lower rate of adverse events [15].

Meta-analysis (2017): Ng, Venkatanarayanan, and Ho published a meta-analysis in the Journal of Affective Disorders confirming that St. John's wort demonstrated significant antidepressant effects compared to placebo and was non-inferior to standard antidepressants [16].

Systematic review (2016): Apaydin et al. conducted a systematic review for the Evidence-based Practice Centers and found consistent evidence supporting the efficacy of St. John's wort for major depressive disorder of mild to moderate severity [17].

Head-to-head trial vs. paroxetine (2005): Szegedi et al. published a landmark randomized controlled trial in the BMJ comparing St. John's wort extract (900 mg/day, escalating to 1,800 mg/day if needed) to the SSRI paroxetine (20 mg/day, escalating to 40 mg/day) in 251 adults with moderate to severe depression. St. John's wort was at least as effective as paroxetine, with the hyperforin-standardized extract showing a trend toward superiority and a higher remission rate [9].

Negative Trials and Severe Depression

Three well-publicized studies found no benefit with St. John's wort, though notably two of these studies also found that the active comparator antidepressant was ineffective:

Hypericum Depression Trial Study Group (2002): This large NIH-funded multicenter trial compared St. John's wort to sertraline (Zoloft) and placebo in patients with moderate to severe major depression. Neither St. John's wort nor sertraline was significantly more effective than placebo, suggesting the study population or design may have been the issue rather than St. John's wort specifically [7][18].

Shelton et al. (2001): Published in JAMA, this trial found no benefit for St. John's wort compared to placebo. The study has been criticized for potentially including patients with more severe depression than St. John's wort is indicated for [19].

The overall evidence pattern is clear: St. John's wort is effective for mild to moderate major depression but should not be relied upon for severe major depression, where standard antidepressants are considered more effective [1][2][3]. The NCCIH notes it is uncertain whether St. John's wort is effective for severe depression or for treatment periods longer than 12 weeks [2].

Menopause Symptoms

Combination with black cohosh (2006): Uebelhack et al. published a study in Obstetrics and Gynecology examining the combination of St. John's wort and black cohosh extracts in menopausal women with depression. The combination significantly improved both menopause symptoms (including hot flashes) and mood compared to placebo [20].

Postmenopausal depression (2019): Eatemadnia et al. conducted an RCT examining Hypericum perforatum for postmenopausal symptoms and depression, demonstrating that St. John's wort effectively reduced depressive symptoms and improved quality of life in postmenopausal women [21].

Meta-analysis (2014): Liu et al. conducted a meta-analysis of Hypericum perforatum preparations for menopause and found evidence supporting the herb's usefulness for menopausal complaints, particularly when combined with other herbal therapies [22].

The NCCIH notes that small numbers of studies suggest St. John's wort may be helpful for hot flashes associated with menopause, though the overall evidence base remains limited [2].

Attention-Deficit/Hyperactivity Disorder (ADHD)

The evidence for St. John's wort in ADHD is mixed and overall negative. A small open-label study in three male teens suggested improvement in hyperactivity and inattention [23], but a more rigorous RCT published in JAMA by Weber et al. (2008) examined 54 children and adolescents with ADHD and found no benefit with 300 mg three times daily compared to placebo over 8 weeks [24]. St. John's wort may also diminish the effectiveness of methylphenidate (Ritalin), creating a potential interaction concern for ADHD patients [25]. The evidence does not support using St. John's wort for ADHD.

Other Conditions

No reliable evidence supports use of St. John's wort for generalized anxiety, social phobia, seasonal affective disorder (SAD), premenstrual syndrome (PMS), chronic pain, or smoking cessation [1][2]. Two separate RCTs found no significant benefit for smoking cessation [27][28]. Limited evidence exists for somatic symptom disorder and irritable bowel syndrome, but the NCCIH considers this insufficient for definitive conclusions [2].

For topical wound healing, a 2024 review in Phytotherapy Research by Farasati Far et al. found promising preclinical evidence (anti-inflammatory and antimicrobial properties) but limited human clinical data [14].

St. John's wort was once popular as a treatment for HIV infection. Current evidence demonstrates it does not help and — critically — can seriously impair standard HIV treatments by reducing blood levels of antiretroviral medications [1][2].

Based on clinical trial evidence, the following dosing regimen has the strongest support:

Preparation Daily Dose Frequency Duration
Standardized extract (0.3% hypericin) 900 mg/day total 300 mg three times daily Minimum 4–6 weeks for initial effect; 8–12 weeks for full assessment [1][8][9]
Standardized extract (0.3% hypericin + 1–3% hyperforin) 900 mg/day total 300 mg three times daily Same timeline [1][9]
Whole herb (dried, powdered) 2–4 g/day Divided doses Less clinical support than standardized extracts [1]

Important Dosing Notes

  • Time to effect: Like conventional antidepressants, St. John's wort requires several weeks of consistent use before full therapeutic effects are achieved. Immediate relief should not be expected [1][2].
  • Dose escalation: In the Szegedi et al. (2005) trial, the dose was escalated from 900 mg/day to 1,800 mg/day if needed after an initial assessment period [9]. Dose increases should only be made under medical supervision.
  • Do not self-treat serious depression: Depression can be a serious illness. The NCCIH emphasizes that anyone who may have depression should consult a healthcare provider [2]. St. John's wort should not substitute for professional mental health care, particularly for moderate to severe depression.
  • Abrupt discontinuation: Do not abruptly stop St. John's wort. Withdrawal symptoms — including headache, nausea, insomnia, fatigue, and irritability — may occur, similar to SSRI discontinuation syndrome [1]. Gradual tapering over 1–2 weeks is recommended.

Limited data suggest the standard antidepressant dose (900 mg/day of standardized extract in divided doses) may also be appropriate for menopause-related symptoms, often in combination with black cohosh [20][22].

Safety and Side Effects

Common Side Effects

For most adults not taking medications, St. John's wort appears safe for up to 12 weeks, with some studies indicating it can be used safely for a year or more [2]. Common side effects are typically mild and infrequent [1][2]:

  • Mild digestive distress (nausea, diarrhea)
  • Headache
  • Fatigue
  • Anxiety
  • Insomnia
  • Skin rashes
  • Dizziness

Comparison with SSRIs: An analysis of adverse drug reactions reported in Australia from 2000 to 2013 found that reactions for St. John's wort were similar in type to those for fluoxetine (Prozac) — most reactions were mild to moderate, including nausea, diarrhea, headache, and fatigue. The total number of reported events was greater for fluoxetine than for St. John's wort (447 vs. 84), though fluoxetine use was estimated to be approximately double that of St. John's wort (Hoban et al., Clin Exp Pharmacol Physiol, 2015) [29].

Serious Side Effects

Serotonin syndrome: When combined with serotonergic medications (SSRIs, SNRIs, tramadol, triptans), St. John's wort can cause life-threatening serotonin syndrome — symptoms include nausea, anxiety, mental confusion, fever, tremor, seizures, altered heart rate, unstable blood pressure, and potentially death [1][29]. This is the most dangerous acute risk associated with St. John's wort.

Mania/bipolar episodes: Like all antidepressants, St. John's wort can trigger manic episodes in people with bipolar disorder [1]. Individuals with known or suspected bipolar disorder should not use St. John's wort.

Anorgasmia: A long-term study by Sarris (Pharmacopsychiatry, 2012) found that St. John's wort use was associated with an increase in anorgasmia (inability to achieve orgasm), a side effect also seen with conventional antidepressants [30].

Hair loss: Use of St. John's wort has been linked to hair loss in case reports, similar to reports with conventional antidepressants [1].

Cognitive impairment at excessive doses: Limited evidence suggests excessive doses might slightly impair mental function, and one case report describes apparent worsening of symptoms of Alzheimer's disease [1].

Photosensitivity

St. John's wort can increase sensitivity to ultraviolet light. Studies in healthy subjects at standard doses did not show clinically significant photosensitivity (Hammerness et al., Psychosomatics, 2003) [31], but individual reports exist of unexpected sunburn and a population survey found an association with cataract development, possibly related to the herb's UV-sensitizing effects (Booth et al., Curr Eye Res, 2009) [32].

It is advisable to avoid prolonged or intense sun exposure while using St. John's wort, particularly for those also taking other photosensitizing drugs such as sulfa antibiotics or piroxicam, as effects may be additive [1].

Withdrawal Symptoms

Abruptly stopping St. John's wort can lead to withdrawal symptoms similar to SSRI discontinuation syndrome: headache, nausea, insomnia, fatigue, and irritability [1]. Gradual dose reduction over 1–2 weeks is recommended when discontinuing.

Special Populations

  • Pregnancy: The NCCIH states that St. John's wort may be unsafe during pregnancy because it may increase the risk of birth defects [2]. It is not recommended for women who are or may become pregnant [1][2].
  • Breastfeeding: Breastfeeding infants of mothers who take St. John's wort can experience colic, drowsiness, and lethargy [2]. The herb is not recommended during breastfeeding.
  • Children: Safety and efficacy have not been well established in children. The Weber et al. (2008) RCT in 54 children and adolescents found no benefit, and the safety profile in pediatric populations is not well characterized [24].

Drug Interactions

Drug interactions are the most significant safety concern with St. John's wort. The herb induces cytochrome P450 enzymes (particularly CYP3A4) and P-glycoprotein, which accelerates the metabolism of many medications and reduces their blood levels and effectiveness [10][11][33]. This interaction mechanism may affect as many as half of all drugs in use today [1].

Medications with Reduced Effectiveness

Medication/Class Clinical Consequence Severity
Cyclosporine, tacrolimus (transplant immunosuppressants) Risk of organ transplant rejection Life-threatening
HIV protease inhibitors and NNRTIs (e.g., indinavir, nevirapine) Worsening of HIV symptoms, viral resistance Life-threatening
Hepatitis C drugs (sofosbuvir/Sovaldi, ledipasvir/Harvoni) Decreased plasma concentration, reduced therapeutic effect, potential viral resistance Life-threatening
Warfarin (Coumadin) Failure of anticoagulation protection, risk of blood clots Life-threatening
Cancer chemotherapy drugs (irinotecan, imatinib, docetaxel) Loss of anti-cancer efficacy Life-threatening
Paxlovid (COVID-19 antiviral) Decreased plasma concentration, loss of virologic response, possible viral resistance Serious
Oral contraceptives / estrogen replacement Unintended pregnancy; decreased hormone replacement drug levels Serious
Digoxin (heart disease treatment) Increased heart disease symptoms Serious
Statin drugs (e.g., simvastatin) Higher cholesterol levels, loss of cardiovascular protection Serious
Anti-psychotic drugs (olanzapine, clozapine) Increased symptoms of psychosis Serious
Anti-seizure drugs (phenytoin, carbamazepine) Reduced seizure control Serious
Heart medications (ivabradine) Reduced cardiac drug effectiveness Serious
Omeprazole (Prilosec) and related proton pump inhibitors Increased ulcer or reflux symptoms Moderate
Methylphenidate (Ritalin) Diminished efficacy of ADHD medication [25] Moderate
Erectile dysfunction drugs (sildenafil/Viagra, tadalafil/Cialis) Reduced effectiveness [34][35] Moderate

Sources: ConsumerLab [1], NCCIH [2], Nicolussi et al. (2020) [10], Soleymani et al. (2017) [11], Czigle et al. (2023) [33], Chan et al. (2023) [36].

Dangerous Combination Interactions

Medication/Class Interaction Risk Mechanism
SSRIs (fluoxetine/Prozac, sertraline/Zoloft, citalopram/Celexa) Serotonin syndrome: nausea, anxiety, confusion, fever, tremor, seizures, altered heart rate, unstable blood pressure, potentially death Additive serotonergic effects
Other antidepressants (SNRIs, tricyclics including amitriptyline, bupropion, MAOIs) Serotonin syndrome or MAOI interaction (rapid heart rate, high blood pressure, delirium) Additive serotonergic or MAOI-like effects
Anti-migraine triptans (sumatriptan) Serotonin syndrome Additive serotonergic effects
Tramadol (painkiller) Serotonin syndrome Additive serotonergic effects
Anesthetics Delayed emergence from anesthesia after surgery Potentiation of anesthetic effects
Photosensitizing drugs (piroxicam, sulfa antibiotics) Increased sun sensitivity Additive photosensitization
MAO inhibitors Rapid heart rate, high blood pressure, delirium MAOI-like interaction

The "Reverse Risk" of Stopping St. John's Wort

A critical but often-overlooked safety concern: if a patient is taking St. John's wort alongside a medication, and their physician has adjusted the medication dosage to account for the enzyme-inducing herb, suddenly stopping St. John's wort can cause blood levels of the medication to rise rapidly, potentially causing toxic side effects [1]. This is because the CYP3A4 enzyme induction reverses when the herb is discontinued, and the medication is no longer being cleared as quickly. This reverse risk applies to all medications affected by St. John's wort's enzyme-inducing properties. Patients should always inform their healthcare provider before starting or stopping St. John's wort.

Interactions with Lab Tests

St. John's wort may interfere with the 24-hour urine 5-HIAA test, used to help diagnose carcinoid syndrome. Patients should inform their physician and laboratory if they take St. John's wort and have been advised to take this test. Patients are typically also advised to avoid tryptophan and serotonin-rich foods such as pineapple, banana, kiwi, plum, tomato, avocado, walnut, hickory nut, and eggplant one to three days before this test (Burks, AACE Clin Case Rep, 2016) [38].

Clinical Relevance Reviews

Nicolussi et al. (2020) published a comprehensive reassessment of St. John's wort drug interactions in the British Journal of Pharmacology, confirming that while many interactions are pharmacokinetically documented, clinical significance varies by medication and patient factors [10].

Soleymani et al. (2017) reviewed the clinical risks of St. John's wort co-administration in Expert Opinion on Drug Metabolism & Toxicology, providing a systematic overview of interaction mechanisms and risk stratification [11].

Czigle et al. (2023) examined pharmacokinetic and pharmacodynamic herb-drug interactions for herbal medicines of the central nervous system, noting that CYP3A4 induction is the primary mechanism underlying most interactions [33].

While the extensive drug interaction list may make St. John's wort appear unusually dangerous, it is more accurate to say it is an especially well-studied herb whose risks are better characterized than most [1]. As a comparison, grapefruit juice causes many of the same CYP3A4-mediated drug interactions and is not ordinarily considered a dangerous substance [1].

Dietary Sources

St. John's wort is not a food ingredient. It is a herbal medicine derived exclusively from the Hypericum perforatum plant and consumed in capsule, tablet, or tincture form [1][2].

Plant Identification

Hypericum perforatum is characterized by:

  • Yellow, five-petaled flowers
  • Opposite leaves with tiny translucent dots visible when held to light (the "perforations" referenced in the species name perforatum)
  • Blooming period around late June (St. John's Day)
  • Found in meadows, fields, roadsides, and disturbed areas

Harvesting and Processing

The flowers and upper leaves are typically harvested at peak bloom. Commercial preparations are made by extracting the dried plant material with solvents (usually ethanol or methanol-water mixtures) to produce standardized extracts. The extraction process concentrates the active constituents (hypericin, hyperforin, flavonoids) while removing some plant fiber, chlorophyll, and contaminants [1][4].

Whole herb preparations use the dried, ground aerial parts without the extraction step. These tend to have lower concentrations of active compounds per gram and may contain higher levels of heavy metals than extracted preparations [1].

References

  1. ConsumerLab. "St. John's Wort Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/st-johns-wort/stjohnswort/
  2. National Center for Complementary and Integrative Health (NCCIH). "St. John's Wort." Updated May 2025. https://www.nccih.nih.gov/health/st-johns-wort
  3. St. John's wort. NatMed Pro website. Accessed at naturalmedicines.therapeuticresearch.com on November 15, 2024.
  4. Nahrstedt A, Butterweck V. "Biologically active and other chemical constituents of the herb of Hypericum perforatum L." Pharmacopsychiatry. 1997;30 Suppl 2:129-134.
  5. Butterweck V. "Mechanism of action of St John's wort in depression: what is known?" Wien Med Wochenschr. 2007;157(13-14):354-358.
  6. Zanoli P. "Role of hyperforin in the pharmacological activities of St. John's Wort." CNS Drug Rev. 2004;10(3):203-218.
  7. Reichling J, Saller R. "Quality control in the manufacturing of modern herbal remedies." Forsch Komplementarmed Klass Naturheilkd. 2003;10(4):188-197.
  8. Linde K, Berner MM, Kriston L. "St John's wort for major depression." Cochrane Database Syst Rev. 2008;(4):CD000448. https://doi.org/10.1002/14651858.CD000448.pub3
  9. Szegedi A, Kohnen R, Dienel A, Kieser M. "Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine." BMJ. 2005;330(7490):503. https://doi.org/10.1136/bmj.38356.655266.82
  10. Nicolussi S, Drewe J, Butterweck V, Meyer zu Schwabedissen HE. "Clinical relevance of St. John's wort drug interactions revisited." Br J Pharmacol. 2020;177(6):1212-1226. https://doi.org/10.1111/bph.14936
  11. Soleymani S, Bahramsoltani R, Rahimi R, Abdollahi M. "Clinical risks of St John's wort (Hypericum perforatum) co-administration." Expert Opin Drug Metab Toxicol. 2017;13(10):1047-1062. https://doi.org/10.1080/17425255.2017.1378342
  12. Linde K, Mulrow CD. "St John's wort for depression." Cochrane Database Syst Rev. 2004. https://doi.org/10.1002/14651858.CD000448.pub2
  13. Zanoli P. "Role of hyperforin in the pharmacological activities of St. John's Wort." CNS Drug Rev. 2004;10(3):203-218.
  14. Farasati Far B, Gouranmohit G, Naimi-Jamal MR, et al. "The potential role of Hypericum perforatum in wound healing: a literature review on the phytochemicals, pharmacological approaches, and mechanistic perspectives." Phytother Res. 2024;38(7):3271-3295. https://doi.org/10.1002/ptr.8182
  15. Zhao X, Zhang H, Wu Y, et al. "The efficacy and safety of St. John's wort extract in depression therapy compared to SSRIs in adults: a meta-analysis of randomized clinical trials." Adv Clin Exp Med. 2023;32(2):151-161. https://doi.org/10.17219/acem/152218
  16. Ng QX, Venkatanarayanan N, Ho CYX. "Clinical use of Hypericum perforatum (St John's wort) in depression: a meta-analysis." J Affect Disord. 2017;210:211-221. https://doi.org/10.1016/j.jad.2016.12.048
  17. Apaydin EA, Maher AR, Shanman R, et al. "A systematic review of St. John's wort for major depressive disorder." Syst Rev. 2016;5(1):148. https://doi.org/10.1186/s13643-016-0325-2
  18. Hypericum Depression Trial Study Group. "Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial." JAMA. 2002;287(14):1807-1814. https://doi.org/10.1001/jama.287.14.1807
  19. Shelton RC, Keller MB, Gelenberg A, et al. "Effectiveness of St John's wort in major depression: a randomized controlled trial." JAMA. 2001;285(15):1978-1986. https://doi.org/10.1001/jama.285.15.1978
  20. Uebelhack R, Blohmer JU, Graubaum HJ, et al. "Black cohosh and St. John's wort for climacteric complaints: a randomized trial." Obstet Gynecol. 2006;107(2 Pt 1):247-255. https://doi.org/10.1097/01.AOG.0000196504.49378.83
  21. Eatemadnia A, Ansari S, Abedi P, Najar S. "The effect of Hypericum perforatum on postmenopausal symptoms and depression: a randomized controlled trial." Complement Ther Med. 2019;45:109-113. https://doi.org/10.1016/j.ctim.2019.05.028
  22. Liu Y-R, Jiang Y-L, Huang R-Q, et al. "Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety." Climacteric. 2014;17(4):325-335. https://doi.org/10.3109/13697137.2013.865721
  23. Niederhofer H. "St. John's wort may improve some symptoms of attention-deficit hyperactivity disorder." Nat Prod Res. 2010;24(3):203-205.
  24. Weber W, Vander Stoep A, McCarty RL, et al. "Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial." JAMA. 2008;299(22):2633-2641. https://doi.org/10.1001/jama.299.22.2633
  25. Niederhofer H. "St. John's wort may diminish methylphenidate's efficacy." Med Hypotheses. 2007;68(5):1189.
  26. Abrishami MH, Noras MR, Soltanifar A, et al. "Clinical evidence for the effectiveness of herbal medicines in the treatment of an obsessive-compulsive disorder: a review study." Curr Drug Discov Technol. 2022;19(5):e160622206086.
  27. Parsons A, Ingram J, Inglis J, et al. "A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to prevent weight gain on smoking cessation." Drug Alcohol Depend. 2009;102(1-3):116-122. https://doi.org/10.1016/j.drugalcdep.2009.02.004
  28. Sood A, Ebbert JO, Prasad K, et al. "A randomized clinical trial of St. John's wort for smoking cessation." J Altern Complement Med. 2010;16(7):761-767. https://doi.org/10.1089/acm.2009.0445
  29. Hoban CL, Byard RW, Musgrave IF. "A comparison of patterns of spontaneous adverse drug reaction reporting with St. John's Wort and fluoxetine during the period 2000-2013." Clin Exp Pharmacol Physiol. 2015;42(7):747-751. https://doi.org/10.1111/1440-1681.12424
  30. Sarris J, Fava M, Schweitzer I, Mischoulon D. "St John's wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder: continuation data from a 26-week RCT." Pharmacopsychiatry. 2012;45(7):275-278. https://doi.org/10.1055/s-0032-1306278
  31. Hammerness P, Basch E, Ulbricht C, et al. "St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist." Psychosomatics. 2003;44(4):271-282. https://doi.org/10.1176/appi.psy.44.4.271
  32. Booth SJ, Rodgers IR. "St. John's wort, sunlight and cataracts." Curr Eye Res. 2009;34(4):324-326.
  33. Czigle S, Nagy M, Mladenka P, et al. "Pharmacokinetic and pharmacodynamic herb-drug interactions — part I. Herbal medicines of the central nervous system." PeerJ. 2023;11:e16149. https://doi.org/10.7717/peerj.16149
  34. Henderson L, Yue QY, Bergquist C, et al. "St John's wort (Hypericum perforatum): drug interactions and clinical outcomes." Br J Clin Pharmacol. 2002;54(4):349-356. https://doi.org/10.1046/j.1365-2125.2002.01683.x
  35. Markowitz JS, Donovan JL, DeVane CL, et al. "Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme." JAMA. 2003;290(11):1500-1504. https://doi.org/10.1001/jama.290.11.1500
  36. Chan W-JJ, Adiwidjaja J, McLachlan AJ, Boddy AV. "Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance." Cancer Chemother Pharmacol. 2023;91(2):103-119. https://doi.org/10.1007/s00280-023-04510-1
  37. Nobakht SZ, Akaberi M, Mohammadpour AH, et al. "Hypericum perforatum: traditional uses, clinical trials, and drug interactions." Iran J Basic Med Sci. 2022;25(9):1045-1058. https://doi.org/10.22038/ijbms.2022.65112.14329
  38. Burks T. "St. John's Wort Interference With 5-Hydroxyindoleacetic Acid Testing." AACE Clin Case Rep. 2016;2(4):e337-e339.

Related Posts

Back to blog